SEOM guidelines for the treatment of bone metastases from solid tumours.
Bone metastases are a common and distressing effect of cancer, being a major cause of morbidity in many patients with advanced stage cancer, in particular in breast and prostate cancer. Patients with bone metastases can experience complications known as skeletal-related events (SREs) which may cause significant debilitation and have a negative impact on quality of life and functional independence. The current recommended systemic treatment for the prevention of SREs is based on the use of bisphosphonates: ibandronate, pamidronate and zoledronic acid- the most potent one- are approved in advanced breast cancer with bone metastases, whereas only zoledronic acid is indicated in advanced prostate cancer with bone metastases. The 2011 ASCO guidelines on breast cancer, recommend initiating bisphosphonate treatment only for patients with evidence of bone destruction due to bone metastases. Denosumab, a fully human antibody that specifically targets the RANK-L, has been demonstrated in two phase III studies to be superior to zoledronic acid in preventing or delaying SREs in breast and prostate cancer and non-inferior in other solid tumours and mieloma; it's convenient subcutaneous administration and the fact that does not require dose adjustment in cases of renal impairment, make this agent an attractive new therapeutic option in patients with bone metastases. Finally, in a phase III study against placebo, denosumab significantly increased the median metastasis-free survival in high risk non-metastatic prostate cancer, arising the potential role of these bone-modifying agents in preventing or delaying the development of bone metastases.
Medical Oncology Department, Hospital Universitario de Guadalajara, Spain. jacaes@sescam.jccm.es
Javier
J
Cassinello Espinosa
Aránzazu
A
González Del Alba Baamonde
Fernando
F
Rivera Herrero
Esther
E
Holgado Martín
D000465:Algorithms; D001859:Bone Neoplasms / Q000175:diagnosis / Q000517:prevention & control / Q000556:secondary* / Q000628:therapy*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D002277:Carcinoma / Q000175:diagnosis / Q000473:pathology / Q000517:prevention & control / Q000628:therapy; D003952:Diagnostic Imaging / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000331:legislation & jurisprudence; D009369:Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D013030:Spain